Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
151.28
-16.25 (-9.70%)
At close: May 6, 2026, 4:00 PM EDT
152.04
+0.76 (0.50%)
After-hours: May 6, 2026, 7:56 PM EDT
Insulet Revenue
Insulet had revenue of $761.70M in the quarter ending March 31, 2026, with 33.87% growth. This brings the company's revenue in the last twelve months to $2.90B, up 31.93% year-over-year. In the year 2025, Insulet had annual revenue of $2.71B with 30.73% growth.
Revenue (ttm)
$2.90B
Revenue Growth
+31.93%
P/S Ratio
3.61
Revenue / Employee
$537,185
Employees
5,400
Market Cap
10.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.71B | 636.50M | 30.73% |
| Dec 31, 2024 | 2.07B | 374.50M | 22.07% |
| Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
| Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
| Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
| Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
| Dec 31, 2019 | 738.20M | 174.40M | 30.93% |
| Dec 31, 2018 | 563.80M | 100.00M | 21.56% |
| Dec 31, 2017 | 463.80M | 96.81M | 26.38% |
| Dec 31, 2016 | 366.99M | 103.10M | 39.07% |
| Dec 31, 2015 | 263.89M | 32.57M | 14.08% |
| Dec 31, 2014 | 231.32M | -15.76M | -6.38% |
| Dec 31, 2013 | 247.08M | 35.72M | 16.90% |
| Dec 31, 2012 | 211.37M | 59.11M | 38.83% |
| Dec 31, 2011 | 152.26M | 55.29M | 57.02% |
| Dec 31, 2010 | 96.97M | 30.93M | 46.85% |
| Dec 31, 2009 | 66.03M | 29.97M | 83.12% |
| Dec 31, 2008 | 36.06M | 22.69M | 169.66% |
| Dec 31, 2007 | 13.37M | 9.71M | 265.06% |
| Dec 31, 2006 | 3.66M | 3.61M | 7,226.00% |
| Dec 31, 2005 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zimmer Biomet Holdings | 8.41B |
| Smith & Nephew | 6.16B |
| STERIS | 5.83B |
| DexCom | 4.82B |
| Bruker | 3.46B |
| Globus Medical | 2.94B |
| Bio-Rad Laboratories | 2.59B |
| Bio-Rad Laboratories | 2.59B |
PODD News
- 19 hours ago - Insulet Earnings Call Transcript: Q1 2026 - Transcripts
- 19 hours ago - Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand - Reuters
- 20 hours ago - Insulet Reports First Quarter 2026 Results - Business Wire
- 1 day ago - Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities - Business Wire
- 2 days ago - Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes - Business Wire
- 7 days ago - FDA Flags High-Risk Recall Of Insulet's Omnipod 5 Pods Over Insulin Delivery Concerns - Benzinga
- 8 days ago - Insulet to Participate in BofA Securities 2026 Health Care Conference - Business Wire
- 5 weeks ago - Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026 - Business Wire